MLN8237
Drug timelines are a Plus or Pro feature.
10 regulatory and trial events tracked for MLN8237, covering 2016-02-09 to 2022-01-19. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer [Phase 1]